Key Takeaways Cresco Labs' Q1 2025 sales fell 10% YoY to $165.8 million, reflecting sustained domestic market challenges. The company's adjusted gross margin slid 220 bps while EBITDA margin dropped to 22% from 28.8% YoY. CRLBF warns of a Q2 revenue dip tied to Illinois system changes despite ongoing expansion efforts.Although Cresco Labs (CRLBF) remains one of the leading vertically integrated multistate cannabis operators in the United States, it has been facing persistent challenges in the domestic mar ...